CavetM.E., VittitowJ.L., ImpagnatielloF., OnginiE., and BastiaE.Nitric oxide (NO): an emerging target for the treatment of glaucoma. Invest. Ophthalmol. Vis. Sci. 55:5005, 2014.
2.
KaufmanP.L.Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. Expert Opin. Pharmacother. 18:433–444, 2017.
3.
ChangR., and WangS.An emerging treatment option for glaucoma: rho kinase inhibitors. Clin. Ophthalmol. 883, 2014. DOI:10.2147/opth.s41000
4.
KanekoY., OhtaM., InoueT., MizunoK., IsobeT., TanabeS., and TaniharaH.Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells. Sci. Rep. 6, 2016. DOI:10.1038/srep19640
5.
US Department of Health and Human Services, Food and Drug Administration. Rhopressa Approval Letter 208254. Received December 18, 2017.
6.
WangR., WilliamsonJ.E., KopczynskiC., and SerleJ.B.Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J. Glaucoma, 24:51–54, 2015.
7.
LewisR.A., LevyB., RamirezN., et al.Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br. J. Ophthalmol. 100:339–344, 2016.
8.
ShawP.X., SangA., WangY., HoD., DouglasC., DiaL., and GoldbergJ.L.Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury. Exp. Eye Res. 158:33–42, 2017.
9.
LiuX., RasmussenC.A., GabeltB.T., BrandtC.R., and KaufmanP.L.Gene therapy targeting glaucoma: where are we?. Surv. Ophthalmol. 54:472–486, 2009.
10.
StamerW.D., LeiY., Boussommier-CallejaA., OverbyD.R., and EthierC.R.ENOS, a pressure-dependent regulator of intraocular pressure. Invest. Opthalmol. Vis. Sci. 52:9438–9444, 2011.